Sign inJoin waitlistJoin the waitlist

Benjamin Bakall

Physician · Associated Retina Consultants LTD

Credentials: · · · · ·

History

Associated Retina Consultants LTD
Present

Medical Retina and Inherited Retinal Dystrophies
2007–2008
Ophthalmology
University of Arizona College of Medicine-Tucson
2004–2007
Preliminary or Transitional Year
2003–2004
Doctor of Medicine
1999–2003

Research

Identification of the gene responsible for Best macular dystrophy
Nature Genetics · 1998 · 586 citations
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
American Journal of Ophthalmology · 2013 · First of 7 authors · 197 citations
Expression of bestrophin-1, the product of the VMD2 gene, modulates voltage-dependent Ca2+ channels in retinal pigment epithelial cells
The FASEB Journal · 2006 · 160 citations

Edwin Stone
6 papers · 1 as a resident
Byron Lam
4 papers
MP
Mark Pennesi
4 papers
Jacque Duncan
3 papers
Vinit Mahajan
3 papers
AN
Aaron Nagiel
2 papers
Alessandro Iannaccone
2 papers
AK
Arshad Khanani
2 papers
Cristy Ku
2 papers · 2 as a resident
Culver Boldt
2 papers · 1 as a fellow
HS
Hendrik Scholl
2 papers
James Folk
2 papers

Clinical trials

A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Site PI · Recruiting · Phase 1, Phase 2
Biojiva LLC
2026–2029
Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)
Site PI · Not yet recruiting · Phase 1, Phase 2
Opus Genetics, Inc
2026–2034
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
Site PI · Recruiting · Phase 3
Ocugen
2026–2031
Study of ALK-001 on the Progression of Stargardt Disease
Site PI · Recruiting · Phase 3
Alkeus Pharmaceuticals, Inc.
2026–2030